John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PWOD
2401
DELISTED
Penns Woods Bancorp
PWOD
| $393K | ﹤0.01% |
20,256
-3,200
| -14% | -$64.6K |
|
2402
Oramed Pharmaceuticals
ORMP
$217M
| $393K | ﹤0.01% |
134,454
-22,876
| -15% | -$64K |
|
2403
Bassett Furniture
BSET
$164M
| $391K | ﹤0.01% |
26,516
+800
| +3% | +$12.3K |
|
2404
Commerce Bancshares
CBSH
$8.35B
| $389K | ﹤0.01% |
+8,064
| New | +$383K |
|
2405
HealthEquity
HQY
$8.81B
| $389K | ﹤0.01% |
4,760
-21,408
| -82% | -$1.67M |
|
|
MRNS
2406
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $387K | ﹤0.01% |
42,834
+1,629
| +4% | +$15.8K |
|
|
TWOU
2407
DELISTED
2U Inc
TWOU
| $387K | ﹤0.01% |
33,088
+16,371
| +98% | +$318K |
|
2408
Reinsurance Group of America
RGA
$16B
| $385K | ﹤0.01% |
1,996
-50,128
| -96% | -$8.75M |
|
|
SSBK
2409
DELISTED
Southern States Bancshares
SSBK
| $385K | ﹤0.01% |
14,844
-13,140
| -47% | -$343K |
|
2410
BlackRock US Equity Factor Rotation ETF
DYNF
$40.9B
| $382K | ﹤0.01% |
+8,600
| New | +$361K |
|
|
CCRD
2411
DELISTED
CoreCard
CCRD
| $381K | ﹤0.01% |
34,453
+8,105
| +31% | +$96.4K |
|
2412
CS Disco
LAW
$271M
| $381K | ﹤0.01% |
46,808
-1,256
| -3% | -$9.63K |
|
2413
Outdoor Holding Co
POWW
$256M
| $380K | ﹤0.01% |
+138,362
| New | +$323K |
|
2414
International Seaways
INSW
$4.91B
| $380K | ﹤0.01% |
7,136
-201,181
| -97% | -$10.4M |
|
|
RSVR
2415
Reservoir Media
RSVR
$655M
| $379K | ﹤0.01% |
47,844
-24,215
| -34% | -$172K |
|
2416
BayCom
BCML
$327M
| $379K | ﹤0.01% |
18,370
-997
| -5% | -$20.6K |
|
2417
PUT
RBC Bearings
RBC
$15.7B
| $378K | ﹤0.01% |
1,400
| – | – |
|
|
RDUS
2418
DELISTED
Radius Recycling
RDUS
| $378K | ﹤0.01% |
+17,899
| New | +$421K |
|
|
STER
2419
DELISTED
Sterling Check Corp. Common Stock
STER
| $378K | ﹤0.01% |
+23,485
| New | +$335K |
|
2420
Applied Optoelectronics
AAOI
$9.61B
| $374K | ﹤0.01% |
26,984
-85,844
| -76% | -$1.45M |
|
2421
SmartRent
SMRT
$276M
| $372K | ﹤0.01% |
138,892
+70,384
| +103% | +$204K |
|
|
SGMO
2422
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $372K | ﹤0.01% |
554,855
-1,619,278
| -74% | -$1.17M |
|
2423
nLIGHT
LASR
$2.5B
| $371K | ﹤0.01% |
28,560
-85,810
| -75% | -$1.12M |
|
2424
Trinity Capital Inc
TRIN
$1.77B
| $370K | ﹤0.01% |
25,210
-347,815
| -93% | -$5.02M |
|
2425
Castle Biosciences
CSTL
$1.07B
| $370K | ﹤0.01% |
16,700
-600
| -3% | -$13.1K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.